Stanford Brain Scans Reveal Two Types of Migraines

For the 37 million Americans living with migraine headaches, finding relief has been nothing short of a guessing game. But Stanford Medicine researchers just changed that by discovering something doctors have never seen before: two distinct biological subtypes of migraine that show up clearly on brain scans.

Dr. Robert Cowan, who led the largest brain imaging study of migraine patients to date, put it bluntly. "Right now, treatment decisions for migraine are worse than trial and error," he said. "It's darts in the dark."

His team scanned the brains of 111 migraine patients and 51 healthy volunteers using functional MRI, which tracks blood flow between brain regions. Then they let computers find patterns in the data without starting with any assumptions about what they'd find.

The imaging revealed something striking. One group of patients, called cluster 2, showed dramatically different blood flow patterns between regions of their brain compared to both healthy people and the other migraine group. These patients also suffered longer-lasting headaches, were older, and faced more disability from their condition.

Here's the surprising part: both subtypes had migraines equally often. That means the current system of labeling migraines as "chronic" (more than 15 headache days per month) or "episodic" (fewer than 15 days) might be missing the bigger picture entirely.

Right now, insurance companies only cover preventive migraine medication for chronic cases. But Cowan suspects many episodic migraine patients in the more severe subtype could benefit from daily preventive treatment too.

The Ripple Effect

This discovery could transform care for millions. The research team is now working to identify clinical signs that match these biological subtypes, so doctors won't need expensive brain scans to classify patients correctly.

Imagine a patient who only gets five migraine days per month but suffers severely. Under today's rules, they probably won't get preventive medication. But if their symptoms match the cluster 2 profile, doctors could confidently prescribe daily treatment that might spare them years of unnecessary pain.

The team is also testing whether these subtypes can predict which patients will develop chronic migraine, potentially allowing doctors to intervene earlier. Blood biomarker studies are underway too, offering another path to quick, accurate diagnosis.

For people who've described migraines as "brain on fire" or "an ice pick through the head," this research offers something precious: the possibility that their first treatment could actually be the right one.